Calliditas Therapeutics AB

Activities: Pharmaceutical

Trending Articles

  1. Lonza appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer As of 1 July 2025, Andreas joins Lonza’s Executive Committee as Chief Legal & Corporate Affairs Officer
  2. Famar Group acquires German sterile injectable production site from MiP Pharma The fill-finish facility will enhance Famar's footprint in aseptic and lyophilised therapeutic production, allowing the company to better serve its European clients
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    How to protect your workers with emergency showers In manufacturing environments where chemical exposure is a constant risk, the safety and well-being of your workforce should be a top priority, reports James Hamilton, Global...
  4. SCHOTT Pharma delivers strong second quarter of fiscal year 2025 SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today published its results for the second quarter of the fiscal year 2025
  5. Next generation module improves flow process automation Vapourtec unveils Reaction Controller and Datalogger module

Upcoming event

CPhI North America

20–22 May 2025 | Exhibition | Pennsylvania, US See all

Related Content

Research & Development

Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon

China's National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression
Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Ingredients

Full details from Calliditas Therapeutics’ Phase 3 study released

Calliditas Therapeutics has announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon delayed release capsules in adults with Primary IgA nephropathy
Drug Delivery

Chinese NMPA accepts Calliditas' partner Everest Medicines NDA

Chronic kidney disease is one of the most serious public health problems in China, where IgAN is estimated by Everest to affect around five million people

Calliditas budesonide therapy approved to reduce proteinuria

Proteinuria is associated with IgAN, however it has not yet been established whether the therapy slows kidney function decline in patients with the condition
Regulatory

Calliditas receives fast track FDA designation for PBC candidate

The FDA program facilitates the expedited development and review of new drugs intended to treat serious or life-threatening conditions
Manufacturing

Calliditas and Everest Medicines enter $120m development deal in China

The agreement gives Everest Medicines exclusive rights to develop and commercialise Nefecon in five countries in East Asia
Subscribe now